Back to News
Market Impact: 0.25
CRISM Therapeutics Reports Wider H1 Loss As Phase 2 Programme Advances
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
CRISM Therapeutics reported an unaudited wider net loss for the six months ended June 30, 2026, versus the prior-year period. The company also issued a clinical update on its implantable biodegradable drug-related program, though the provided article excerpt does not disclose specific financial figures or trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
More News
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- +17% in a single session: This AI-picked stock catches a data-center breakout
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- Intel surges 12% as CPU stocks rally. Here's what's driving the move
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)